The presence of DNA damage initiates signaling through the ataxia-telangiectasia mutated kinase (ATM) and the ATM-and the Rad3-related kinase (ATR), which phosphorylate, thus activating, the checkpoint kinases (Chk) 1 and 2, which leads to cell cycle arrest. The bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is cytotoxic primarily by inducing DNA monoadducts and ultimately, interstrand cross-links, which block DNA replication. In this study, we investigated the activation of the ATR-Chk1 pathway in response to BCNU treatment and the dependence of this response on the DNA mismatch repair (MMR) capacity. Medulloblastoma cells were exposed to low and moderate doses of BCNU, and the effects on this DNA damage signaling pathway were examined. In response to BCNU, Chk1 was found to be phosphorylated at serine 345 and exhibited increased kinase activity. Caffeine and wortmannin, which are broad-spectrum inhibitors of ATM and ATR, reduced this phosphorylation. Cell cycle analysis further revealed an accumulation of cells in the S phase in response to BCNU, an effect that was attenuated by caffeine. Small interfering RNA knockdown of ATR also reduced Chk1 phosphorylation after exposure to BCNU. However, knockdown of ATM had no effect on the observed Chk1 phosphorylation, suggesting that ATR was primarily responsible for Chk1 activation.
serine 345 and exhibited increased kinase activity. Caffeine and wortmannin, which are broad-spectrum inhibitors of ATM and ATR, reduced this phosphorylation. Cell cycle analysis further revealed an accumulation of cells in the S phase in response to BCNU, an effect that was attenuated by caffeine. Small interfering RNA knockdown of ATR also reduced Chk1 phosphorylation after exposure to BCNU. However, knockdown of ATM had no effect on the observed Chk1 phosphorylation, suggesting that ATR was primarily responsible for Chk1 activation.
Analysis of Chk1 activation in cells deficient in MMR proteins
MutL␣ or MutS␣ indicated that the DNA damage response induced by BCNU was independent of the MMR apparatus. This MMR-independent activation seems to be the result of DNA interstrand cross-link formation.
The bifunctional DNA alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) has been an important component of multiple agent adjuvant chemotherapy regimens in the treatment of brain tumors. Because of its high lipophilicity, it has the capacity to cross the blood-brain barrier, essential for any brain tumor therapy. The primary cytotoxic effects of BCNU result from alkylation at the O 6 position of guanine in DNA, and the subsequent conversion of these monoadducts into DNA interstrand cross-links between the N 1 -position of guanine in one strand and the N 3 position of cytosine in the opposite strand of DNA (Fischhaber et al., 1999) . Monoadducts are also formed as a result of alkylation at the N 7 and N 1 positions of guanine, as well as at the phosphotriester backbone.
The ataxia-telangiectasia-mutated kinase (ATM) and the ATM-and Rad3-related kinase (ATR) are members of the phosphatidylinositol-3-kinase-related kinase (PIKK) family (Abraham, 2004) . Checkpoint kinase 1 (Chk1) is a major effector of normal S-phase progression and is also involved in G 2 /M-phase checkpoint signaling in response to DNA damage (Bartek and Lukas, 2003) . ATM and, mainly, ATR have been shown to be upstream activators of Chk1 in response to various types of genotoxic stress (Abraham, 2004) . The DNA damage response to DNA methylating agents of the unimolecular nucleophilic substitution (S N 1) type, like temozolomide, has been relatively well defined (Caporali et al., 2004; Stojic et al., 2004a Stojic et al., ,b, 2005 . At low doses, these agents activate the ATR-Chk1 pathway in a manner that is dependent upon the presence of an intact DNA mismatch repair (MMR) apparatus. However, at high doses, this activation becomes independent of the MMR system. It has been further established that the DNA adduct O 6 -methylguanine (O 6 -MeG) provides the major signal for the elicited DNA damage signaling response (Yoshioka et al., 2006) .
The formation of DNA interstrand cross-links produces a physical block to both replication and transcription, because the two DNA strands are unable to unwind, which accounts for the high toxicity of antitumor agents that produce these lesions. Because of this replication block, it is not surprising that cells are unable to progress through S phase. For agents such as photoactivated psoralens and mitomycin C, S-phase arrest is not merely a result of mechanical stalling of replication forks but is caused by the activation of the S-phase checkpoint (Joerges et al., 2003; Mladenov et al., 2007) . The S-phase arrest is regulated by the ATR kinase, which mediates arrest through two parallel pathways, one involving Chk1 and the other involving DNA repair proteins NBS1-FANCD2 (Fanconi anemia, complementation group D2), actively effecting cell cycle arrest at the S phase (Pichierri and Rosselli, 2004) .
Although the mechanisms whereby BCNU exerts its cytotoxicity are relatively well defined, the DNA damage signaling pathway that is activated in response to BCNU treatment remains largely unelucidated. As a bifunctional DNA alkylating agent, BCNU inflicts two major types of DNA damage upon the cell: DNA monoadducts and interstrand cross-links. We hypothesized that, unlike temozolomide, low doses of BCNU could activate the ATR-Chk1 pathway in a manner that is independent of the MMR apparatus because DNA interstrand cross-links induced by BCNU present a block to the replicating DNA forks. In this study, we have evaluated the effect of BCNU on the ATR-Chk1 pathway and its dependence on the MMR system in MMR-proficient or -deficient medulloblastoma or rhabdomyosarcoma cells. We have demonstrated that Chk1 is activated largely through ATR and that this activation is independent of DNA MMR proteins and likely to be triggered by DNA interstrand cross-links.
Materials and Methods
Chemicals and Reagents. BCNU (Sigma, St. Louis, MO), temozolomide (Schering-Plough, Kenilworth, NJ), O 6 -benzylguanine (O 6 -BG) (kindly supplied by Dr. Robert C. Moschel, National Cancer Institute, Bethesda, MD) and wortmannin were dissolved in dimethyl sulfoxide and freshly prepared each time before use. Caffeine (Sigma) was dissolved in phosphate-buffered saline.
Cell Lines and Limiting Dilution Assay. The medulloblastoma cell lines D341 MED, D341 MED (BR), D283 MED, D487 MED, and Daoy and the rhabdomyosarcoma cell lines TE-671 and TE-671 (OTR) were maintained in improved minimal essential medium, zinc option (Richter's modification) (Invitrogen, Carlsbad, CA) supplemented with 20% fetal bovine serum (Invitrogen). Human cervical carcinoma cell line HeLa was maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum. The cytotoxicity of BCNU against D341 MED cells was determined by the limiting dilution assay as described previously (Friedman et al., 1992) .
Drug Treatments. For drug treatments, logarithmically growing cells were used and incubated with various concentrations of BCNU, temozolomide, caffeine, or wortmannin for the time periods indicated followed by washing in fresh medium and subsequent incubation. Where indicated, cells were pulsed with 100 M O 6 -BG for 10 min before treatment with BCNU or temozolomide and maintained in 10 M O 6 -BG. O 6 -Alkylylguanine DNA Alkyltransferase Activity Assay. The activity of AGT was measured as described previously (Dolan et al., 1990 Immunoblotting Studies. Whole-cell extracts for immunoblot analyses were prepared as described previously (Stommel and Wahl, 2004) . The following antibodies were used for immunoblotting studies: anti-AGT antibody (Kamiya Biochemical Co., Seattle, WA), anti-MSH2 antibody (Calbiochem, La Jolla, CA), anti-MSH6 antibody (BD Biosciences, San Jose, CA), anti-MLH1 antibody (Calbiochem), anti-PMS2 antibody (Calbiochem), anti-ATR antibody (GeneTex, San Antonio, TX), anti-ATM antibody (Gene Tex), anti-Chk1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-phosphoChk1 (Ser345) antibody (Cell Signaling Technology, Danvers, MA). Immunoblotting studies were carried out as described previously (Schild-Poulter et al., 2003) .
Checkpoint Kinase Activity Assay. D341 MED or Daoy cells were treated with 20 M BCNU and, 24 h after treatment, whole-cell extracts were prepared as described previously (Stommel and Wahl, 2004) and immunoprecipitations using anti-Chk1 antibody (Santa Cruz Biotechnology) were carried out as previously depicted (SchildPoulter et al., 2003) . Equal amounts of total protein (500 g) were immunoprecipitated using the indicated antibodies. Assay for the activities of immunoprecipitated Chk1 was performed using K-LISA Checkpoint Activity Kit as instructed by the manufacturer (Calbiochem).
Small Interfering RNA Transfection Assays. The siRNA sequences for Chk1 (Zhao and Piwnica-Worms, 2001 ) and for ATM and ATR (Zhang et al., 2005) were described previously and supplied by Dharmacon (Lafayette, CO). The siRNA sequence for nonspecific control was 5Ј-AUGAACGUGAAUUGCUCAAUU-3Ј (Dharmacon). The siRNA sequences for MLH1 were a pool of three target-specific siRNA sequences (Santa Cruz Biotechnology). For transfection experiments, logarithmically growing D341 MED or Daoy cells were plated in 60-mm dishes at a density of 1 ϫ 10 6 cells per dish in Opti-MEM (Invitrogen). After 24 h, cells were transfected with the indicated siRNA duplexes at a final concentration of 67 nM by using Oligofectamine (Invitrogen). Cells were typically used for experiments after 48 to 72 h of siRNA treatment.
Cell-Cycle Analysis. Treated cells were washed once with phosphate-buffered saline, trypsinized, and washed again in phosphatebuffered saline with 2% fetal bovine serum and fixed in ice-cold ethanol for at least 1 h at Ϫ20°C, washed, and stained with propidium iodide (30 g/ml) and treated with RNase (0.6 mg/ml) in phosphate-buffered saline plus 0.5% (v/v) Tween 20 and 2% fetal bovine serum. Stained cells were analyzed on a FACSCalibur flow cytometer (BD Biosciences) using Cellquest software, and the ModFit program (Verity Software House Inc., Topsham, ME) was used to analyze the cell-cycle profiles.
Results
Bifunctional DNA Alkylator BCNU Activates Chk1 in Human Medulloblastomas. D341 MED was established in our laboratory from a cerebellar medulloblastoma and is defective in DNA MMR (Bacolod et al., 2004) . Our previous study established that high doses of BCNU (100-600 M) caused extensive lethalities in D341 MED cells (Bacolod et al., 2002 ). In the current study, we performed limiting dilution assays on D341 MED cells with low doses of BCNU from 5 to 20 M. We established that BCNU was cytotoxic to D341 MED cells with an LD 50 of approximately 12 M (Fig. 1A) .
Chk1 is activated in response to various types of DNA
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at ASPET Journals on October 13, 2017 molpharm.aspetjournals.org damage and undergoes phosphorylation at serine 317 or 345 (Zhao and Piwnica-Worms, 2001 ). To investigate whether DNA damage induced by low doses of BCNU could activate Chk1, we exposed D341 MED cells to BCNU over a 100-fold range of concentration from 0.2 M to 20 M. Then, 16 to 24 h after drug exposure, cell lysates were prepared and immunoblotted with phospho-specific antibody against phosphoserine 345 of human Chk1. We detected phosphorylated Chk1 in D341 MED cells exposed to BCNU at doses as low as 2 M (Fig. 1B) , indicating that the kinase was activated. We then examined the time course of Chk1 activation by BCNU in D341 MED cells and found that, after exposure to BCNU, the phosphorylated form of Chk1 appeared as early as 4 h, peaked around 16 to 24 h, and was almost undetectable by 48 h (Fig. 1C) . We extended our observations to three other medulloblastoma cell lines, D283 MED, Daoy, and D487 MED and detected phosphorylation of Chk1 at serine 345 in all three cell lines treated with 20 M BCNU and in Daoy and D487 MED cells treated with 2 M BCNU ( 6 -chloroethylguanine and O 6 -hydroxyethylguanine formed in DNA treated by BCNU can be dealkylated by the DNA repair protein AGT (Pegg, 2000) . O 6 -BG is a low-molecular-weight substrate of AGT and inactivates the protein (Dolan et al., 1990; Pegg, 2000) , and pretreatment of cells expressing AGT with O 6 -BG sensitizes them to BCNU. The level of AGT protein expression varies in different medulloblastoma cell lines. D341 MED, Daoy, and D487 MED cells all expressed AGT, in contrast to D283 MED cells, which did not ( Fig. 2A ). D341 MED (BR) is a BCNU-resistant subline of D341 MED. It was generated in our laboratory by treating D341 MED cells with escalating doses of BCNU over time and its increased BCNU resistance is due to a very high level of AGT. AGT activity assays showed that D487 MED, D341 MED, and D341 MED (BR) exhibited an AGT activity of 870 Ϯ 80, 93 Ϯ 13, and 1530 Ϯ 100 fmol/mg of protein, respectively. D341 MED (BR) and D487 MED cells were exposed to 100 M O 6 -BG for 10 min before treatment with 20 M BCNU and maintained in 10 M O 6 -BG, a treatment protocol that reduces AGT activities essentially to zero (Bacolod et al., 2002) . Chk1 phosphorylation was not observed after treatment with BCNU alone in the high-AGT-expressing D341 MED (BR) cells (Fig. 2B) . When AGT was inactivated by O 6 -BG in these cells, Chk1 phosphorylation was notably increased. In D487 MED cells, without O 6 -BG treatment, we observed a low level of Chk1 phosphorylation after BCNU treatment; however, maximal phosphorylation was observed only when the cellular AGT had been inactivated by O 6 -BG. These results demonstrate that the modulation of AGT by O 6 -BG potentiates Chk1 activation by BCNU, thus indicating that alkylation at the O 6 position of guanine or the subsequently formed DNA interstrand cross-links are the primary BCNU-induced DNA lesions that trigger Chk1 activation.
ATR Is an Upstream Activator of Chk1 in Response to BCNU. ATM and ATR play overlapping roles in activating Chk1 in response to genotoxic stress, ATR being the major upstream activator of Chk1. Caffeine, a broad-spectrum inhibitor of the PIKK family, has been shown to inhibit the activities of both ATM and ATR (Hall-Jackson et al., 1999; Sarkaria et al., 1999) . Wortmannin is another broad-spec- trum inhibitor of the PIKK family, with ATR being least sensitive to its inhibition (Abraham, 2004) . To identify the upstream activator(s) of Chk1 in response to BCNU, we explored the cotreatment of D341 MED cells with caffeine or wortmannin and BCNU. D341 MED cells were exposed to 20 M BCNU with or without 10 mM caffeine, and cells were collected after 6 to 8 h and examined for Chk1 phosphorylation. The results showed that phosphorylated Chk1 was markedly reduced in BCNU-treated D341 MED cells by the addition of caffeine (Fig. 3A) . A similar result was observed when cells were treated with wortmannin (Fig. 3B ). These results demonstrate that Chk1 activation by BCNU is sensitive to inhibition of the PIKK family. As caffeine and wortmannin are broad-spectrum inhibitors of PIKK, we transfected D341 MED or Daoy cells with siRNA against ATM, ATR, or scrambled RNA for 48 to 72 h followed by exposure to 20 M BCNU for 4 to 6 h. Immunoblotting studies with anti-ATR or anti-ATM antibody showed that siRNA against ATR or ATM effectively reduced the level of ATR or ATM in D341 MED cells (Fig. 3C) . In these cells, we observed levels of phosphorylated Chk1 induced by BCNU in untransfected cells that were similar to levels in cells transfected with scrambled RNA or siRNA against ATM (Fig. 3C ). There was a noticeable reduction in the phosphorylation of Chk1 induced by BCNU in D341 MED cells transfected with siRNA against ATR. Likewise, phosphorylation of Chk1 was markedly reduced in Daoy cells transfected with siRNA against ATR compared with controls or those transfected with scrambled RNA or siRNA against ATM (Fig. 3D) . These findings indicate that the phosphorylation of Chk1 is dependent upon ATR, which functions upstream of Chk1 in response to the DNA damage caused by BCNU.
Chk1 Activation by BCNU Is Independent of MMR. In the current study, we established that low doses of BCNU activated the ATR-Chk1 pathway in human medulloblastoma cell lines. Daoy cells were previously shown to have functional MMR, whereas D341 MED cells were MMR-deficient (Bacolod et al., 2004) . D283 MED was also defective in MMR activity, a consequence of deficiency in the MMR polypeptides MLH1 and PMS2 (Dong et al., 1999) . Immunoblotting of the cell lysates from D341 MED, Daoy, D487 MED, and D283 MED with antibodies against the MMR proteins MutL␣ and MutS␣ revealed the two subunits of MutS␣ (MSH2 and MSH6) to be present in all four cell lines and the two subunits of MutL␣ (MLH1 and PMS2) to be present only in Daoy and D487 MED (Fig. 4A) . No MLH1 and low levels of PMS2 were detected in D341 MED and D283 MED cells, which accounts for the lack of MMR activity observed in these two cell lines.
To determine the MMR dependence of BCNU activation of Chk1, we treated MutL␣-deficient D283 MED cells and MutL␣-proficient Daoy cells with 20 M BCNU or 20 M temozolomide. We observed Chk1 activation by BCNU in both D283 MED and Daoy cells (Fig. 4B) . As expected, Chk1 activation by temozolomide was present in MutL␣-proficient Daoy cells, but was undetectable in MutL␣-deficient D283 cells, which confirms that DNA monoadducts formed from exposure to temozolomide do not activate Chk1 in a MutL␣-deficient background. TE-671 (OTR) is a temozolomide-resistant subclone of the rhabdomyosarcoma cell line TE-671 that was established in our laboratory. Immunoblotting studies with anti-MSH2 and MSH6 antibodies revealed a lack of expression of MutS␣ in TE-671 (OTR) (Fig. 4C ). Because both cell lines express high levels of AGT (S. Johnson, unpublished results), we pretreated the paired rhabdomyosarcoma cell lines TE-671 and TE-671 (OTR) with 100 M O 6 -BG for 10 min before exposure to 25 M O 6 -BG with 20 M BCNU. Chk1 phosphorylation was observed after BCNU treatment in both MutS␣-proficient TE-671 and MutS␣-deficient TE-671 (OTR) cells, whereas temozolomide induced the phosphorylation of Chk1 only in MutS␣-proficient TE-671 cells (Fig. 4D) .
Because D283 (Fig. 4, E and F) . The level of Chk1 phosphorylation in response to BCNU in Daoy cells transfected with siRNA against MLH1 showed no difference from that in the untreated Daoy cells or the cells transfected with scrambled RNA (Fig. 4F) , suggesting that BCNU signaling through the ATR-Chk1 pathway is not dependent upon the MMR apparatus. On the other hand, there was a noticeable reduction in the level of Chk1 phosphorylation in response to temozolomide in Daoy cells transfected with siRNA against MLH1 than that in the untreated Daoy cells or the cells transfected with scrambled RNA, suggesting the dependence upon a functional MMR apparatus of the ATR-Chk1 signaling elicited by temozolomide. Altogether, the above findings suggest that DNA interstrand cross-links induced by BCNU contribute to the activation of the ATR-Chk1 pathway in an MMRindependent manner, whereas O 6 -MeG or O 6 -ethylguanine adducts require the presence of an intact MMR apparatus to activate the ATR-Chk1 pathway.
BCNU Induces an Accumulation of Medulloblastoma Cells in the S Phase. S N 1-type DNA methylators have been shown to induce a prolonged cell cycle arrest at the second G 2 /M phase (Caporali et al., 2004) . To assess cell cycle perturbations caused by BCNU, we investigated the effects of low doses of BCNU on cell-cycle progression in medulloblastoma cells. D341 MED cells were exposed to 20 M BCNU and at 4 to 72 h after treatment were processed for cell cycle analysis by flow cytometry. The results showed that the percentage of cells in the S phase increased from 27.54% before treatment to a peak of 49.21% 24 h after treatment (Fig. 5A) . We also observed an increase in the number of cells in the S phase in other medulloblastoma cell lines 24 h after BCNU treatment: D283 MED (31 Ϯ 3%, control group; 42 Ϯ 2%, BCNU group), D487 MED (34 Ϯ 1%, control group; 44 Ϯ 2%, BCNU group), and Daoy (52 Ϯ 1%, control group; 82 Ϯ 1%, BCNU group). These findings indicated that BCNU induced an accumulation of medulloblastoma cells in the S phase, suggesting an activation of an intra-S-phase checkpoint.
Because Chk1 phosphorylation in response to BCNU was inhibited by caffeine, we further assessed the effects of caffeine on BCNU-induced cell cycle perturbations. D341 MED cells were treated with 20 M BCNU alone or in combination with 3, 5, or 10 mM caffeine. The percentage of D341 MED cells in the S phase was 41% in the BCNU group and 25% in the control group (Fig. 5B ). Caffeine at 3, 5, or 10 mM decreased BCNU-treated D341 MED cells in the S phase to 34, 27, and 27%, respectively. These data suggest that the S phase block resulting from BCNU treatment is attenuated by caffeine, a broad inhibitor of PIKK kinases.
Discussion
The DNA damage signaling response to BCNU has been largely undefined. In the current study, we addressed this by examining the DNA damage checkpoint response induced by the bifunctional DNA alkylator BCNU. We established that DNA interstrand cross-links induced by BCNU activate the ATR-Chk1 pathway. We further demonstrated that, unlike S N 1-type DNA methylators, the activation of the ATR-Chk1 pathway by BCNU is independent of the MMR system. Furthermore, our data indicate that, in response to DNA damage induced by low doses of BCNU, there is an activation of intra-S-phase checkpoint. Chk1 is a major effector of normal S-phase progression, and ATR, a pivotal upstream regulator of Chk1, activates Chk1 by phosphorylating it at serine 317 and 345 in response to DNA damage (Zhao and Piwnica-Worms, 2001; Bartek and Lukas, 2003) . S N 1-type DNA methylators, such as temozolomide or N-methyl-NЈ-nitro-N-nitroso-guanidine, signal through ATR, which phosphorylates, thus activating, the downstream effector kinase Chk1 and triggering a cell cycle arrest at the second G 2 /M checkpoint (Caporali et al., 2004; Stojic et al., 2004a; Adamson et al., 2005) . The O 6 -MeG DNA adducts formed from exposure to S N 1-type methylators provide the major signal for the activation of the ATR-Chk1 pathway (Yoshioka et al., 2006) and are also the major elicitor of apoptotic responses in cells (Hickman and Samson, 2004) . The activation of the ATR-Chk1 pathway and the G 2 /M checkpoint by low doses of S N 1-type DNA methylators and the triggered apoptotic responses hinge upon a functional MMR apparatus (Hickman and Samson, 2004; Stojic et al., 2004b) . A recent study has also shown that whereas temozolomide-induced apoptosis was dependent upon the presence of MMR proteins, the cell death induced by the DNA bifunctional alkylator 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea showed no such dependence on MMR proteins (Takagi et al., 2008) .
BCNU induces two major types of genotoxic damage to the cell: DNA monoadducts and DNA interstrand cross-links. The O 6 -ethylguanine adducts produced by BCNU could activate the ATR-Chk1 pathway in a fashion similar to that demonstrated by O 6 -MeG. We also observed Chk1 phosphorylation in cells treated with the monofunctional alkylator ethylnitrosourea only if they were MMR-competent (B. Cui, unpublished results). The ATR-Chk1 DNA damage signaling pathway has been shown to be activated by DNA lesions such as those caused by ultraviolet light that stall replication forks (Stiff et al., 2006) , and it has also been observed to be activated by other agents, including photoactivated psoralens and mitomycin C, that induce DNA interstrand crosslinks; however, these types of activation are independent of DNA MMR (Akkari et al., 2000; Pichierri and Rosselli, 2004) . Although psoralens, mitomycin C, BCNU, and phosphoramide mustard all produce DNA interstrand cross-links, the physical structures of these interstrand cross-links are quite dissimilar. It would seem likely that the stalled replication forks, rather than recognition of the DNA interstrand crosslinks, result in the MMR-independent activation of the ATRChk1 pathway.
Chk1 has been implicated in the control of the intra-Sphase checkpoint (Zhao et al., 2002; Robinson et al., 2006) , and ATR is a key member of the intra-S-phase checkpoint pathway in response to genotoxic stress (Cliby et al., 2002) . DNA damage detected during S phase rapidly slows down S-phase progression and ongoing DNA synthesis. DNA damage may be readily repaired by homologous recombination in the S phase because replication intermediates are perfect substrates for recombination repair (Johnson and Jasin, 2000) . DNA interstrand cross-links induced by photoactivated psoralens have been shown to elicit the activation of S-phase checkpoint (Akkari et al., 2000; Pichierri and Rosselli, 2004) , and these cross-links are repaired in the context of DNA replication during S phase (Cipak et al., 2006) . BCNU has been shown to induce sister chromatid exchanges, and there has been good correlation between cytotoxicity and induction of sister chromatid exchanges for bifunctional nitrosoureas (Biegel et al., 1982 ). In the current study, we have shown that BCNU induced a dramatic accumulation of medulloblastoma cells in the S phase, suggesting the activation of an intra-S-phase checkpoint. These observations together suggest that DNA interstrand cross-links induced by BCNU contribute to the activation of an intra-S-phase checkpoint, which slows down S-phase progression to allow repair of DNA damage.
However, there have been conflicting results about the effect of BCNU or other bifunctional nitrosoureas on cell cycle checkpoint activation. Another bifunctional DNA alkylator, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, was found to induce a dramatic accumulation of HeLa cells in the S phase 24 h after exposure to 25 M concentrations of the drug and a marked accumulation of a PMS2-deficient subclone of HeLa cells in the S phase 24 h after exposure to 12.5 M BCNU (Aquilina et al., 1999) , suggesting that the activation of S-phase checkpoint by the bifunctional nitrosourea is independent of the MMR apparatus. On the other hand, BCNU with O 6 -BG was shown to elicit a prolonged cell cycle arrest at the G 2 /M checkpoint in two MMR-deficient cell lines, HCT116 and HCT 15 (Yan et al., 2005) . This study used a high dose of BCNU (50 M). At low doses of S N 1 methylators, activation of the ATR-Chk1 pathway occurs only in MMR proficient cells. In contrast, high doses of S N 1methylators have been shown to trigger an MMR-independent activation of the ATR-Chk1 pathway and G 2 /M checkpoint as observed by others (Stojic et al., 2005) .
From the results of this study and the observations by others, we propose the following model for DNA damage signaling response to the bifunctional DNA alkylator BCNU. In both MMR-proficient tumors and MMR-deficient tumors, the BCNU-induced stalled replication forks that result from DNA interstrand cross-links signal to the upstream activator ATR to phosphorylate Chk1 and induce the activation of an intra-S-phase checkpoint. Thus, S-phase progression is halted so that DNA repair can proceed. If DNA repair cannot be effected, the cells are committed to die. One important implication arising from these observations is that pretreatment with S-phase-specific inhibitors may potentiate BCNUinduced cytotoxicity. In this regard, the broad-spectrum PIKK inhibitor caffeine was shown to effect a 10-fold potentiation of BCNU cytotoxicity in both BCNU-sensitive and BCNU-resistant cells (Aida and Bodell, 1987) .
The effectiveness of BCNU has been hampered by the emergence of resistance in tumors during treatment. Besides high levels of AGT activities in tumors that affect the clinical response of gliomas to BCNU (Esteller et al., 2000) , there are other unknown mechanisms of resistance at work (Silber et al., 1992; Bacolod et al., 2002 Bacolod et al., , 2004 . Recent study has shown that BCNU-resistant cancer cells may be sensitized to temozolomide as a result of the development of enhanced MMR capacity (Yamauchi et al., 2008) . Further investigations will be required to provide insight into the repair mechanisms of DNA interstrand cross-links and their contribution to BCNU resistance. The next crucial question to be resolved is the determination of what proteins activate ATR in response to DNA interstrand cross-links, the elucidation of which would provide potential novel molecular targets for drug development.
